Peripheral Arterial Disease Clinical Trial
Official title:
Exercise Rehabilitation for Critical Limb Ischemia Patients After Revascularization: Pilot Randomized Controlled Trial Assessing Functional Capacity and Quality of Life After a 12-week Rehabilitation Program Versus Best Medical Therapy
Peripheral arterial disease (PAD) affects more than 200 million people worldwide. This disease occurs with narrowing and occlusion of arteries supplying oxygenated blood to the organs and limbs. Symptomatic patients typically experience leg pain with physical activity. More advanced disease states are referred to as critical limb ischemia (CLI), where patients may have leg pain at rest or non-healing wounds. Primary treatment of PAD involves risk factor management; smoking cessation, management of blood pressure, blood cholesterol, diabetes, and exercise prescription. Patients with CLI typically require interventions to reestablish blood supply to their limbs. There is currently minimal understanding of the role for exercise rehabilitation after revascularization procedures in this vulnerable population. This is the first clinical to understand the role of exercise for these patients. We hypothesize that exercise rehabilitation after revascularization will improve quality of life and functional capacity in these patients.
Background: Peripheral arterial disease (PAD) refers to narrowing and occlusion of arteries
supplying oxygenated blood to non-coronary and non-intracranial circulatory systems. This
term is typically used to describe disease in the legs though it also affects upper
extremities, renal and mesenteric vessels. Symptomatic patients typically experience leg pain
with walking or physical activity which is referred to as intermittent claudication (IC). In
more advanced chronic disease states with severely compromised blood flow to the tissues,
patients may have leg pain at rest or even non healing wounds that can lead to tissue loss
which is defined as critical limb ischemia (CLI).
Risk factor management is critical for PAD patients with the goal of improving symptoms and
preventing disease progression. This includes smoking cessation as well as appropriate
management for hypertension, dyslipidemia and diabetes. Antiplatelet therapy should be
initiated in symptomatic patient or when other risk factors are present. Exercise
interventions should be encouraged in all patients with PAD. In patients who have progressed
to critical limb ischemia, treatment goals are to relieve pain, heal wounds and prevent limb
loss. In addition to risk factor management and medical therapy, these patients require
revascularization procedures. Depending on the extent and location of disease, the techniques
used may be endovascular/interventional (minimally invasive), surgical, or a hybrid
combination of the two.
There has been minimal research examining exercise rehabilitation after revascularization.
There are no studies that have focused on exercise rehabilitation exclusively in patients
with CLI.
Purpose/Objectives: The aim of this study is to develop a better understanding of the role
for supervised exercise rehabilitation programs (SEP) in PAD-CLI patients after
revascularization. This pilot study will assess the feasibility for expanding this research
to a larger randomized controlled trial.
Study Design:
This is a two-phase, single-center, non-blinded randomized controlled trial.
Objectives:
In phase 1, the investigators will assess feasibility. Specifically, the investigators will
assess rate of enrollment, barriers to participation and any methodological challenges that
may require changes. If phase 1 of this study shows reasonable rates of enrollment and no
methodological challenges, we will proceed to phase 2.
Key objectives for phase 2 are as follows:
1. The primary objective is to show how SEP affects functional capacity and quality of life
in patients with PAD-CLI after revascularization.
2. The secondary objective is to show how SEP affects the rate of major adverse limb events
(MALE) and improve survival in patients with PAD-CLI after revascularization.
Hypotheses: 1) PAD-CLI patients who have undergone revascularization will have a greater
improvement in functional capacity and quality of life compared with patients treated with
best medical therapy alone.
2) PAD-CLI patients who have undergone revascularization will have fewer MALE and improved
survival compared with patients treated with best medical therapy alone.
Methodology: Patients included in the study will be identified in the vascular surgery
outpatient clinic or through emergency department as requiring revascularization secondary to
critical limb ischemia. Patients will be approached regarding study participation prior to
the revascularization procedure. After eligibility is confirmed and patients have signed
informed consent, patients will be randomized to one of two groups:
1. Best Medical Therapy (BMT): Appropriate risk factor management, encouragement to
mobilize.
2. Supervised Exercise Program (SEP): consist of BMT plus a supervised exercise program.
Patients will undergo evaluation of functional capacity assessment using a graded treadmill
test at the outset of the study and after 12 weeks of either BMP or SEP. The investigators
will also administer a validated quality of life (QoL) questionnaire to the two different
groups at the outset and completion of the study. Patients will be followed annually to
monitor for MALE and survival.
Statistics: Normally distributed data will be presented as mean ± SD. Results at baseline and
12 weeks will be compared using a paired t-test. For data that is not normally distributed,
comparisons will be performed using a non-parametric Mann-Whitney test. Comparisons will be
accepted as statistically significant at 95% confidence level (p≤0.05). STATA software will
be used for statistical analysis.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06032065 -
Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD)
|
Phase 3 | |
Active, not recruiting |
NCT03987061 -
MOTIV Bioresorbable Scaffold in BTK Artery Disease
|
N/A | |
Recruiting |
NCT03506633 -
Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
|
N/A | |
Active, not recruiting |
NCT03506646 -
Dietary Nitrate Supplementation and Thermoregulation
|
N/A | |
Active, not recruiting |
NCT04677725 -
NEtwork to Control ATherothrombosis (NEAT Registry)
|
||
Recruiting |
NCT05961943 -
RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients
|
N/A | |
Recruiting |
NCT06047002 -
Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
|
||
Completed |
NCT03185052 -
Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach
|
N/A | |
Recruiting |
NCT05992896 -
A Study of Loco-Regional Liposomal Bupivacaine Injection
|
Phase 4 | |
Completed |
NCT04635501 -
AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial
|
N/A | |
Recruiting |
NCT04584632 -
The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery
|
N/A | |
Withdrawn |
NCT03994185 -
The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease
|
N/A | |
Withdrawn |
NCT03538392 -
Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
|
||
Recruiting |
NCT02915796 -
Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty
|
Phase 1 | |
Active, not recruiting |
NCT02900924 -
Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
|
||
Completed |
NCT02901847 -
To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities.
|
N/A | |
Not yet recruiting |
NCT02387450 -
Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT02455726 -
Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease
|
N/A | |
Withdrawn |
NCT02126540 -
Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries
|
N/A | |
Completed |
NCT02384980 -
Saving Life and Limb: FES for the Elderly With PAD
|
Phase 1 |